These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36758550)

  • 41. Outcome of 177 Lu-PSMA Radionuclide Treatment in Advanced Prostate Cancer and Its Association With Clinical Parameters : A Single-Center Experience.
    Has Simsek D; Kuyumcu S; Karadogan S; Ozkan ZG; Isik EG; Basaran M; Sanli MO; Sanli Y
    Clin Nucl Med; 2022 Aug; 47(8):e521-e528. PubMed ID: 35543629
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy.
    Michalski K; Kosmala A; Werner RA; Serfling SE; Seitz AK; Lapa C; Buck AK; Hartrampf PE
    Ann Nucl Med; 2024 Feb; 38(2):87-95. PubMed ID: 37891376
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
    Müller C; Umbricht CA; Gracheva N; Tschan VJ; Pellegrini G; Bernhardt P; Zeevaart JR; Köster U; Schibli R; van der Meulen NP
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1919-1930. PubMed ID: 31134301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
    Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
    Yaxley WJ; McBean R; Wong D; Grimes D; Vasey P; Frydenberg M; Yaxley JW
    Investig Clin Urol; 2021 Nov; 62(6):650-657. PubMed ID: 34729965
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
    Schlenkhoff CD; Knüpfer E; Essler M; Ahmadzadehfar H
    Clin Nucl Med; 2016 Jul; 41(7):572-3. PubMed ID: 26909718
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Third-line treatment and
    von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response to [ 177 Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases.
    Zisser L; Yu J; Oszwald A; Wollenweber T; Kretschmer-Chott E; Grubmüller B; Kramer G; Shariat SF; Mitterhauser M; Vraka C; Hacker M; Haug AR; Rasul S
    Nucl Med Commun; 2022 Nov; 43(11):1113-1120. PubMed ID: 36120814
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of
    Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
    Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
    [No Abstract]   [Full Text] [Related]  

  • 50. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer.
    Fendler WP; Reinhardt S; Ilhan H; Delker A; Böning G; Gildehaus FJ; Stief C; Bartenstein P; Gratzke C; Lehner S; Rominger A
    Oncotarget; 2017 Jan; 8(2):3581-3590. PubMed ID: 27683041
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with
    Xue S; Gafita A; Dong C; Zhao Y; Tetteh G; Menze BH; Ziegler S; Weber W; Afshar-Oromieh A; Rominger A; Eiber M; Shi K
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4064-4072. PubMed ID: 35771265
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Excellent Response to Full-Dose 177 Lu-PSMA-617 RLT in Metastatic Castration-Resistant Prostate Cancer With Transplant Kidney : A Step Ahead.
    Mahdi RA; Aggarwal P; Kumar S; Sood A; Paul D; Mittal BR
    Clin Nucl Med; 2023 Oct; 48(10):e470-e471. PubMed ID: 37566811
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The value of tumor markers in men with metastatic prostate cancer undergoing [
    Yordanova A; Linden P; Hauser S; Feldmann G; Brossart P; Fimmers R; Essler M; Holdenrieder S; Ahmadzadehfar H
    Prostate; 2020 Jan; 80(1):17-27. PubMed ID: 31579967
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Sathekge M; Bruchertseifer F; Knoesen O; Reyneke F; Lawal I; Lengana T; Davis C; Mahapane J; Corbett C; Vorster M; Morgenstern A
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):129-138. PubMed ID: 30232539
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
    Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
    J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
    [No Abstract]   [Full Text] [Related]  

  • 56. Prediction of response and survival after standardized treatment with 7400 MBq
    Rasul S; Hartenbach M; Wollenweber T; Kretschmer-Chott E; Grubmüller B; Kramer G; Shariat S; Wadsak W; Mitterhauser M; Pichler V; Vraka C; Hacker M; Haug AR
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1650-1657. PubMed ID: 33128131
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Delayed response after repeated
    Rahbar K; Bögeman M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):243-246. PubMed ID: 29134280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
    Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
    Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
    [No Abstract]   [Full Text] [Related]  

  • 59. 225 Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177 Lu-PSMA-617 Radioligand Therapy : Pilot Experience From a Prospective Registry.
    Rosar F; Burgard C; Rohloff LV; Blickle A; Bartholomä M; Maus S; Petto S; Schaefer-Schuler A; Ezziddin S
    Clin Nucl Med; 2024 Jul; 49(7):621-629. PubMed ID: 38769643
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate-Specific Membrane Antigen Radioligand Therapy Using
    Schuchardt C; Zhang J; Kulkarni HR; Chen X; Müller D; Baum RP
    J Nucl Med; 2022 Aug; 63(8):1199-1207. PubMed ID: 34887335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.